GNCA News and Press, Genocea Biosciences Inc. From 05/16/19

CAMBRIDGE, Mass., May 16, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc . (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced a research collaboration with Iovance Biotherapeutics, Inc. to assess the potential of applying Genoce...

Post-vaccination immune responses detected to 93% of vaccine neoantigens  in first three patients analyzed Additional data to be presented June 1 st at ASCO 2019 and discussed on a conference call and webcast on June 3 rd CAMBRIDGE, Mass., May 16, 2019 (GLOBE NEWSWIRE)...

Iovance Biotherapeutics (NASDAQ: IOVA ) is up  28%  premarket on light volume in reaction to new interim data from clinical trials evaluating its tumor-infiltrating lymphocyte (TIL) candidates. The data will be presented at ASCO in Chicago. More news on: Iovance Biotherapeutics...

Genocea Biosciences, Inc. (GNCA) Q1 2019 Earnings Conference Call April 30, 2019 09:00 ET Company Participants Dan Ferry - LifeSci Advisors Chip Clark - President & CEO Diantha Duvall - CFO Tom Davis - Chief Medical Officer Jessica Flechtner - CSO Conference Call Parti...

Genocea Biosciences (NASDAQ: GNCA ): Q1 GAAP EPS of -$0.15 misses by $0.07. More news on: Genocea Biosciences, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

Company anticipates presenting first GEN-009 immunogenicity data at ASCO 2019 Conference call today at 9:00 am ET CAMBRIDGE, Mass., April 30, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc . (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunot...

CAMBRIDGE, Mass., April 23, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, will host its first-quarter 2019 financial results and corporate update conference call and live audio webcast on Tu...

Preface In September 2018, I contributed to Vision and Value's blog article GR-MD-02: Keytruda's Partner . A long read, but a very good source of essential research if I do say so myself… More articles have come out since by both Vision and Value and First Genesis Consulting , whi...

CAMBRIDGE, Mass., April 03, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced that Chip Clark, president and chief executive officer, will present a corporate overview at the 18 ...

CAMBRIDGE, Mass., April 02, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc . (NASDAQ: GNCA), a biopharmaceutical company developing neoantigen cancer immunotherapies, today announced the presentation of data from ATLAS™, its ex vivo platform for comprehensively profiling pati...